News
![Does a Big Looming Liability for AT&T Put Its Dividend in Danger?: https://g.foolcdn.com/editorial/images/740659/telecom-worker-installing-5g-network.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODVjYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2b03315439f2d6de7300ef9b045f0e881e97a5ab/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/telecom-worker-installing-5g-network.jpg?locale=us)
Does a Big Looming Liability for AT&T Put Its Dividend in Danger?
Telecom stocks are often reliable income investments to own, but investors aren't so sure that's the case with AT&T (NYSE: T). The stock yields 7.6% right now, as its share price has fallen 19% this
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Biotest AG: Biotest increases EBIT to Euro 19.8 million
![Why Sage Therapeutics Stock Is Tumbling Today: https://g.foolcdn.com/editorial/images/741314/stock-crashing.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVZjYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c23a74c5326878df34475b32fe85058d246f2eda/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/stock-crashing.jpg?locale=us)
Why Sage Therapeutics Stock Is Tumbling Today
Shares of the brain-health specialist Sage Therapeutics (NASDAQ: SAGE) are having a tough trading session today. Specifically, the biotech's stock was down by approximately 13% on heavy volume as of
![AT&T; (T) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
AT&T; (T) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
AT&T (NYSE: T)Q2 2023 Earnings CallJul 26, 2023, 8:30 a.m. ET
Operator
Source Fool.com
![2 Stocks That Raised Their Guidance in July: https://g.foolcdn.com/editorial/images/740653/investor-checking-stocks-on-his-phone.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1JiYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ca5aeba9191afef1ebdb9b092f2f85797367b428/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-checking-stocks-on-his-phone.jpg?locale=us)
2 Stocks That Raised Their Guidance in July
One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ:
![3 Stocks to Buy While They Are on Sale: https://g.foolcdn.com/editorial/images/740937/man-in-wheelchair-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK3BhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f104edd98042c40dbc9a1bf248dc8ebfbcd2e61b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/man-in-wheelchair-laptop.jpg?locale=us)
3 Stocks to Buy While They Are on Sale
There's one main downside to the tremendous performance of the stock market so far in 2023. Many stocks are now priced for perfection. And unfortunately, perfection is rarely attainable.
The good
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Down 97%, Is It Finally Time to Buy Invitae Stock?: https://g.foolcdn.com/editorial/images/740909/doctors-looking-at-tablet.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2hhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--93e1b7316e79569857395479c3458d7075c6e593/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctors-looking-at-tablet.jpg?locale=us)
Down 97%, Is It Finally Time to Buy Invitae Stock?
If you've only recently learned about Invitae (NYSE: NVTA), you can consider yourself lucky. A few years ago, the diagnostics business wowed Wall Street with plans to bring genetic testing to the
![Why Biogen Stock Got Sick Today: https://g.foolcdn.com/editorial/images/741175/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHBhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15ed896907ff10302046031e33ae1f40dc03360e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg?locale=us)
Why Biogen Stock Got Sick Today
Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB)
![Biogen (BIIB) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Biogen (BIIB) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q2 2023 Earnings CallJul 25, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![2 Top Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/740455/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEZhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6ce34392b4d512c5e7335600abcc3ec98ebfb46c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=us)
2 Top Dividend Stocks to Buy and Hold Forever
There are several reasons many investors gravitate toward dividend stocks. Some are attracted to the regular income stream, while others opt for dividend reinvestment to boost long-term returns
![3 Red Flags for AT&T's Future: https://g.foolcdn.com/editorial/images/740710/att_retail_chicago.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN1JaYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e34d5302145d11d6761728d6674fa988b6226191/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att_retail_chicago.jpg?locale=us)
3 Red Flags for AT&T's Future
Over the past two years, AT&T (NYSE: T) tried to reset its business by selling its non-core assets and spinning off DirecTV and WarnerMedia. It claimed that a big reversal of its media expansion
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Will Qualcomm Be a Trillion-Dollar Stock by 2030?: https://g.foolcdn.com/editorial/images/740834/semiconductor-board.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMU5aYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1568f50c6cd208fce86f7b6dd05f57f3f776ac67/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/semiconductor-board.jpg?locale=us)
Will Qualcomm Be a Trillion-Dollar Stock by 2030?
Nvidia became the world's first trillion-dollar chipmaker this May, making it more than three times more valuable than Intel and Advanced Micro Devices combined. Nvidia's valuation skyrocketed to
![Is AT&T's 8.2% Dividend Yield Safe?: https://g.foolcdn.com/editorial/images/740764/att-stock-has-8-dividend-yeild.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOGhZYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6ebecc3e42537f9d81a1ea073c8d109379602e2b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att-stock-has-8-dividend-yeild.png?locale=us)
Is AT&T's 8.2% Dividend Yield Safe?
Fool.com contributor Parkev Tatevosian evaluates AT&T's (NYSE: T) prospects to determine whether its dividend payments are sustainable in the long run.
*Stock prices used were the afternoon prices
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer lowers full-year outlook
![Better Big Biotech Buy: Vertex vs. Biogen: https://g.foolcdn.com/editorial/images/740745/gettyimages-scientists-in-lab01.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXhZYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--743d9995eeab835aa5f0ee4238dac4bace22ee95/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-scientists-in-lab01.jpg?locale=us)
Better Big Biotech Buy: Vertex vs. Biogen
When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Should Income Investors Buy This Blue Chip Stock?: https://g.foolcdn.com/editorial/images/740451/a-customer-shops-at-a-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHhYYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0e0b1c6b6da0777fd19e49799059b70d7b8b5c99/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-customer-shops-at-a-pharmacy.jpg?locale=us)
Should Income Investors Buy This Blue Chip Stock?
For a dividend investor, generating enough income to become and stay financially independent (higher passive income than expenses) comes down in large part to the longevity of the businesses in an
![3 Small-Cap Stocks That Could Be Big-Time Winners: https://g.foolcdn.com/editorial/images/740630/scientists-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2hYYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7a6d20afe5b5d02fac78b597bbef68f5c71d2aa0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-in-a-lab.jpg?locale=us)
3 Small-Cap Stocks That Could Be Big-Time Winners
Think small. It's one of the best ideas for investors seeking to reap returns that trounce the overall market.
Three Motley Fool contributors identified small-cap stocks that they think could
![Viatris Stock: Bull vs. Bear: https://g.foolcdn.com/editorial/images/740374/gettyimages-scientists-in-lab02.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3RYYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e2fa90e17c39e96daeaba62fb8c6ac0617893230/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-scientists-in-lab02.jpg?locale=us)
Viatris Stock: Bull vs. Bear
Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec
![Need an Extra $4,000 in Dividends Each Year? Invest $68,000 in These 3 Stocks.: https://g.foolcdn.com/editorial/images/739961/a-couple-reviewing-a-statement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTlXYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--96d8ca91d02b192813d617014e4f9fcde5b7749b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-statement.jpg?locale=us)
Need an Extra $4,000 in Dividends Each Year? Invest $68,000 in These 3 Stocks.
In retirement, seniors on average see an annual shortfall of about $4,000 between the income they generate and the expenses they incur, according to data from the Bureau of Labor Statistics
![2 Soaring Stocks With More Upside Potential: https://g.foolcdn.com/editorial/images/740120/physician-giving-a-high-five-to-a-young-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0ZXYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--50e193ed7e983d7b2576bd2c978dabc7398c5dc0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-a-high-five-to-a-young-patient.jpg?locale=us)
2 Soaring Stocks With More Upside Potential
Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for
![If You'd Invested $1,000 in AT&T in 2022, This Is How Much You'd Have Today: https://g.foolcdn.com/editorial/images/740365/att_retail_chicago.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1JXYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fbba9756b79f4311b28641f09dbf257bbbb422eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att_retail_chicago.jpg?locale=us)
If You'd Invested $1,000 in AT&T in 2022, This Is How Much You'd Have Today
Last April, AT&T (NYSE: T) spun off WarnerMedia and merged it with Discovery to create new-media giant Warner Bros. Discovery (NASDAQ: WBD). That spinoff, along with its divestment of DirecTV in